In February 2015, Suzlon had just completed its financial and asset restructuring, following financial default after rapid growth through debt financed acquisitions in the financial boom ending in 2008. The restructuring resulted in a significant decrease in the promoter’s equity stake. Suzlon now has to decide how to respond to an offer by the Dilip Sanghvi Group, promoters of Sun Pharma, to acquire a large equity stake in Suzlon for Rs.1,800 crore. If Suzlon were to accept the offer then both the existing promoters and the Dilip Sanghvi group would have the same stake of about 22% each.